Regulatory Approval (as Intangible Asset)

An intangible asset for which there is no foreseeable limit to the period over which it is expected to generate net cash inflows for the entity. Under IAS 38 and ASC 350, indefinite-lived intangible assets are not amortised but must be tested for impairment at least annually and whenever there is an indication of impairment.

An identifiable intangible asset representing the value of unfulfilled orders or contracts at the date of a business combination. Backlog intangibles are recognised separately under purchase price allocation and are amortised as the underlying orders are fulfilled.

The economic return generated by a company's intangible asset base, expressed as income attributable to intangible assets divided by their estimated value. Yield on intangible assets provides a measure of how effectively a firm is monetising its intellectual property, brand, customer relationships, and other non-physical resources.

The application of biological sciences to develop products, processes, and services across sectors including pharmaceuticals, biotechnology, medical devices, agricultural technology, and environmental science. Biosciences companies are among the most intangible-asset-intensive businesses in the global economy, with value concentrated in patents, regulatory approvals, clinical trial data, proprietary compounds, and specialised human capital.

A regulatory authorisation permitting a firm to issue electronic money — digitally stored monetary value representing a claim on the issuer. In the UK, e-money licences are granted by the FCA under the Electronic Money Regulations 2011.

In a business context, the natural environment and the regulatory, social, and market conditions within which organisations operate. Environmental considerations have become increasingly material to intangible asset valuation as ESG (Environmental, Social, and Governance) frameworks gain prominence among investors, regulators, and customers.

The regulatory categorisation system that assigns medical devices to classes based on their risk to patients, which determines the level of regulatory scrutiny required for market approval. The EU MDR uses four classes (I, IIa, IIb, III) while the FDA uses three (I, II, III).

A controlled testing environment established by a financial regulator that allows fintech companies and other innovators to test new products, services, or business models with real customers under relaxed regulatory requirements for a limited period. The FCA launched the first regulatory sandbox in 2016, and the concept has since been adopted by over 50 jurisdictions globally.

What are the main types of intangible assets?

IFRS 3 and ASC 805, the business combination standards, group intangible assets into five illustrative classes: marketing-related, customer-related, artistic-related, contract-based and technology-based. The list is not exhaustive.

What is useful life and how is it estimated?

Useful life is the estimated period an intangible asset will generate economic benefits — determined by technology obsolescence, market dynamics, and contractual terms.

How do you value a company's assembled clinical trial data in a pharma acquisition?

Assembled clinical trial data is valued using the cost approach (reproduction cost of conducting equivalent trials) or as a component of IPR&D value (its contribution to de-risking the pipeline asset).